Trademark: 88292621
Word
BIO3CBD
Status
Dead
Status Code
602
Status Date
Tuesday, October 13, 2020
Serial Number
88292621
Mark Type
4000
Filing Date
Thursday, February 7, 2019
Abandoned Date
Friday, September 25, 2020

Trademark Owner History

Classifications
5 dietary and nutritional supplements, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietary and nutritional supplements, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietary and nutritional supplements featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ointments, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ointments, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ointments featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; pharmaceuticals, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for pharmaceuticals, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; pharmaceuticals featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic foods, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietetic foods, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic foods featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietetic beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic beverages featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; functional beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for functional beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; functional beverages featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease
BIO THREE CBD

Trademark Events
Oct 13, 2020
Abandonment Notice E-Mailed - Failure To Respond
Oct 13, 2020
Abandonment - Failure To Respond Or Late Response
Mar 24, 2020
Notification Of Final Refusal Emailed
Mar 24, 2020
Final Refusal E-Mailed
Mar 24, 2020
Final Refusal Written
Mar 11, 2020
Teas/Email Correspondence Entered
Mar 11, 2020
Correspondence Received In Law Office
Mar 11, 2020
Assigned To Lie
Mar 5, 2020
Teas Response To Office Action Received
Sep 12, 2019
Notification Of Non-Final Action E-Mailed
Sep 12, 2019
Non-Final Action E-Mailed
Sep 12, 2019
Non-Final Action Written
Sep 9, 2019
Assigned To Examiner
Mar 7, 2019
Assigned To Examiner
Mar 1, 2019
New Application Office Supplied Data Entered In Tram
Feb 11, 2019
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24